Clinical Trial Update: Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of Imovax Rabies and VERORAB regimens for pre-exposure and simulated post-exposure prophylaxis in healthy vol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rabies Prophylaxis

Drugs mentioned

• Imovax Rabies (rabies vaccine (inactivated))
• Verorab (rabies vaccine (inactivated))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Healthy Volunteers (Rabies Immunization) | Phase 3 | Status: COMPLETED